Product Name
CANT1, siRNA
Full Product Name
CANT1 siRNA (Rat)
Product Synonym Names
SRAPY; Soluble calcium-activated nucleotidase 1; SCAN-1; Apyrase homolog
Product Gene Name
CANT1 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q8K4Y7
Specificity
CANT1 siRNA (Rat) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of rat CANT1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of CANT1 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
CANT1 sirna
siRNA to inhibit CANT1 expression using RNA interference
Applications Tested/Suitable for CANT1 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for CANT1. It may not necessarily be applicable to this product.
NCBI Accession #
NP_653355.1
[Other Products]
NCBI GenBank Nucleotide #
NM_144754.2
[Other Products]
UniProt Primary Accession #
Q8K4Y7
[Other Products]
UniProt Secondary Accession #
Q4V8N9[Other Products]
UniProt Related Accession #
Q8K4Y7[Other Products]
Molecular Weight
45,659 Da
NCBI Official Full Name
soluble calcium-activated nucleotidase 1
NCBI Official Synonym Full Names
calcium activated nucleotidase 1
NCBI Official Symbol
Cant1??[Similar Products]
NCBI Official Synonym Symbols
srapy
??[Similar Products]
NCBI Protein Information
soluble calcium-activated nucleotidase 1
UniProt Protein Name
Soluble calcium-activated nucleotidase 1
UniProt Synonym Protein Names
Apyrase homolog
Protein Family
Soluble calcium-activated nucleotidase
UniProt Gene Name
Cant1??[Similar Products]
UniProt Synonym Gene Names
Srapy; SCAN-1??[Similar Products]
UniProt Entry Name
CANT1_RAT
NCBI Summary for CANT1
hydrolyzes nucleoside 5'-diphosphates in the order UDP >GDP = IDP >>>CDP but not ADP, may be involved in glycosylation reactions related to quality control in the endoplasmic reticulum [RGD, Feb 2006]
UniProt Comments for CANT1
CANT1: Calcium-dependent nucleotidase with a preference for UDP. The order of activity with different substrates is UDP > GDP > UTP > GTP. Has very low activity towards ADP and even lower activity towards ATP. Does not hydrolyze AMP and GMP. Involved in proteoglycan synthesis. Defects in CANT1 are the cause of Desbuquois dysplasia (DBQD). A chondrodysplasia characterized by severe prenatal and postnatal growth retardation (less than -5 SD), joint laxity, short extremities, progressive scoliosis, round face, midface hypoplasia, prominent bulging eyes. The main radiologic features are short long bones with metaphyseal splay, a 'Swedish key' appearance of the proximal femur (exaggerated trochanter), and advance carpal and tarsal bone age. Two forms of Desbuquois dysplasia are distinguished on the basis of the presence (type 1) or absence (type 2) of characteristic hand anomalies: an extra ossification center distal to the second metacarpal, delta phalanx, bifid distal thumb phalanx, and phalangeal dislocations. Belongs to the apyrase family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Hydrolase; Membrane protein, integral; Nucleotide Metabolism - pyrimidine; Nucleotide Metabolism - purine; EC 3.6.1.6; Endoplasmic reticulum
Cellular Component: endoplasmic reticulum membrane; integral to membrane
Molecular Function: signal transducer activity; calcium ion binding; uridine-diphosphatase activity
Biological Process: positive regulation of I-kappaB kinase/NF-kappaB cascade; proteoglycan biosynthetic process; signal transduction
Research Articles on CANT1
1. soluble apyrase as well as the glomerular ENTPD1 are sensitive to oxidant stress, which may explain their downregulation in the ischemic condition in vivo. However, soluble 5'-nucleotidase and E5NT seem much less sensitive to ROS
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
